Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing covers the month of October 2025, specifically detailing share repurchases executed on October 2, 2025. The transaction was conducted through BNP Paribas SA as part of an existing buyback programme under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial statements. Key metrics for the transaction on October 2, 2025, include:
- Shares Purchased: 335,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,638.50 GBp; highest price paid was 1,683.00 GBp.
- Average Price: Volume-weighted average price paid was 1,655.37 GBp.
- Treasury Holdings: Following this purchase, GSK holds 248,366,844 ordinary shares in treasury.
- Shares in Issue: 4,067,040,496 ordinary shares (excluding treasury shares).
- Voting Rights: Treasury shares represent 6.11% of the total voting rights.
Since September 30, 2025, the company has purchased a total of 902,000 ordinary shares. The filing does not provide data on revenue, profit, cash flow, margins, or debt levels.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury stock due to the buyback programme. The filing does not contain comparative financial data against prior periods to assess changes in operational performance.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that projections are subject to risks and uncertainties that may cause actual results to differ materially. Specific risks are referenced in the "Risk Factors" section of GSK's Annual Report on Form 20-F for 2024 and the Q2 Results for 2025. No new specific guidance or management commentary on future financial performance is provided in this document.
Investor Verification Checklist
- Verify the total cost of the buyback programme and remaining authorization limits.
- Confirm the impact of the 6.11% treasury holding on future dividend calculations and earnings per share (EPS).
- Review the referenced 2024 Form 20-F and 2025 Q2 Results for detailed risk factors and financial performance context.
- Monitor subsequent filings for updates on the buyback programme's progress and completion date.